KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Receivables (2020 - 2025)

Esperion Therapeutics' Receivables history spans 6 years, with the latest figure at $140.2 million for Q4 2025.

  • For Q4 2025, Receivables rose 74.93% year-over-year to $140.2 million; the TTM value through Dec 2025 reached $140.2 million, up 74.93%, while the annual FY2025 figure was $140.2 million, 74.93% up from the prior year.
  • Receivables reached $140.2 million in Q4 2025 per ESPR's latest filing, up from $119.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $140.2 million in Q4 2025 to a low of $21.7 million in Q3 2021.
  • Average Receivables over 5 years is $54.3 million, with a median of $41.7 million recorded in 2023.
  • Peak YoY movement for Receivables: surged 85.13% in 2021, then grew 12.86% in 2022.
  • A 5-year view of Receivables shows it stood at $22.9 million in 2021, then soared by 47.07% to $33.7 million in 2022, then skyrocketed by 43.78% to $48.5 million in 2023, then soared by 65.26% to $80.1 million in 2024, then skyrocketed by 74.93% to $140.2 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Receivables are $140.2 million (Q4 2025), $119.0 million (Q3 2025), and $107.7 million (Q2 2025).